An adapted program of colorectal cancer screening--7 years experience and cost-benefit analysis

The Czech program of colorectal cancer screening differs from most foreign programs in a number of points. The age interval of screened population was limited to 45 to 60 years. Screening was multicentric, with one reference center. More than 95% of the subjects screened were asymptomatic employees...

Full description

Saved in:
Bibliographic Details
Published inHepato-gastroenterology Vol. 41; no. 5; p. 413
Main Authors Fric, P, Zavoral, M, Dvoráková, H, Zoubek, V, Roth, Z
Format Journal Article
LanguageEnglish
Published Greece 01.10.1994
Subjects
Adenocarcinoma - diagnosis
Adenocarcinoma - epidemiology
Adenocarcinoma - prevention & control
Adenocarcinoma - therapy
Age Factors
Colonic Neoplasms - diagnosis
Colonic Neoplasms - epidemiology
Colonic Neoplasms - prevention & control
Colonic Neoplasms - therapy
Colonoscopy
Cost-Benefit Analysis
Female
Humans
Incidence
Male
Mass Screening - economics
Mass Screening - methods
Middle Aged
Neoplasm Staging
Occult Blood
Program Development
Rectal Neoplasms - diagnosis
Rectal Neoplasms - epidemiology
Rectal Neoplasms - prevention & control
Rectal Neoplasms - therapy
Reproducibility of Results
Time Factors
Online AccessGet more information

Cover

More Information
Summary:The Czech program of colorectal cancer screening differs from most foreign programs in a number of points. The age interval of screened population was limited to 45 to 60 years. Screening was multicentric, with one reference center. More than 95% of the subjects screened were asymptomatic employees of various factories, boards and institutions. Total colonoscopy was the primary procedure in all Haemoccult-positive subjects. Some 109,213 subjects received 3 Haemoccult slides. Compliance was 83.1%, and Haemoccult was positive in 2.92% of the subjects. The diagnostic program revealed 347 (13.1%) cancers, 763 adenomas in 592 (22.2%) subjects, and other bleeding conditions in 1043 (39.2%) persons. Dukes A or B colorectal cancer was found in two-thirds of the screened subjects and in only one-third of non-screened symptomatic patients. Average diagnostic and therapeutic costs were almost the same in both groups. Gross national product savings realized by one asymptomatic subject were 315,540 Czechoslovak Crowns (approximately 18,560 US-dollars at the 1989 exchange rates). The adapted program was found to be effective, and its use in a population with a high incidence of colorectal neoplasia deserves consideration.
ISSN:0172-6390